| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
138,140,000 |
| Market
Cap: |
142.28(M) |
| Last
Volume: |
3,241,097 |
Avg
Vol: |
3,286,692 |
| 52
Week Range: |
$0.92 - $1.31 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 807 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Spectrum Pharmaceuticals is a biopharmaceutical company. Co. is engaged in acquiring, developing, and commercializing targeted oncology therapies. Co. has two drugs in late-stage development: Eflapegrastim, which is a long-acting granulocyte colony-stimulating factor for the treatment of chemotherapy-induced neutropenia; as well as Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
50,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$22,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
32,387 |
490,738 |
| Total Sell Value |
$0 |
$0 |
$35,496 |
$343,474 |
| Total People Sold |
0 |
0 |
1 |
7 |
| Total Sell Transactions |
0 |
0 |
1 |
19 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brennan Nora |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
14,277 |
29,277 |
|
- |
|
| Riga Thomas J |
EVP, COO & CCO |
• – – |
2021-05-14 |
4 |
AS |
$3.07 |
$6,908 |
D/D |
(2,250) |
406,879 |
|
-31% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2021-05-14 |
4 |
AS |
$3.07 |
$1,612 |
D/D |
(525) |
311,934 |
|
-31% |
|
| Riga Thomas J |
EVP, COO & CCO |
• – – |
2021-05-13 |
4 |
AS |
$3.09 |
$10,499 |
D/D |
(3,402) |
409,129 |
|
-25% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2021-05-13 |
4 |
AS |
$3.09 |
$1,339 |
D/D |
(434) |
312,459 |
|
-25% |
|
| Vacirca Jeff L |
Director |
– • – |
2021-04-07 |
4 |
A |
$3.15 |
$63,000 |
D/D |
20,000 |
145,967 |
|
- |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2021-04-01 |
4 |
AS |
$3.30 |
$7,260 |
D/D |
(2,200) |
312,893 |
|
-29% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2021-03-31 |
4 |
AS |
$3.20 |
$5,565 |
D/D |
(1,739) |
315,093 |
|
-27% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2021-03-16 |
4 |
AS |
$3.69 |
$60,213 |
D/D |
(16,318) |
316,832 |
|
-10% |
|
| Gustafson Kurt A |
EVP & Chief Financial Officer |
• – – |
2021-03-16 |
4 |
AS |
$3.69 |
$60,213 |
D/D |
(16,318) |
400,451 |
|
-10% |
|
| Riga Thomas J |
EVP, COO & CCO |
• – – |
2021-03-16 |
4 |
AS |
$3.69 |
$69,475 |
D/D |
(18,828) |
412,531 |
|
-10% |
|
| Turgeon Joseph W. |
CEO & President |
• • – |
2021-03-16 |
4 |
AS |
$3.69 |
$104,217 |
D/D |
(28,243) |
565,028 |
|
-10% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2021-03-16 |
4 |
AS |
$3.69 |
$69,475 |
D/D |
(18,828) |
353,017 |
|
-10% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2021-03-15 |
4 |
AS |
$3.63 |
$52,062 |
D/D |
(14,362) |
333,150 |
|
-11% |
|
| Gustafson Kurt A |
EVP & Chief Financial Officer |
• – – |
2021-03-15 |
4 |
AS |
$3.63 |
$73,823 |
D/D |
(20,365) |
416,769 |
|
-11% |
|
| Riga Thomas J |
EVP, COO & CCO |
• – – |
2021-03-15 |
4 |
AS |
$3.63 |
$84,430 |
D/D |
(23,291) |
431,359 |
|
-11% |
|
| Turgeon Joseph W. |
CEO & President |
• • – |
2021-03-15 |
4 |
AS |
$3.63 |
$145,330 |
D/D |
(40,091) |
593,271 |
|
-11% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2021-03-15 |
4 |
AS |
$3.63 |
$82,037 |
D/D |
(22,631) |
371,845 |
|
-11% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2021-02-22 |
4 |
AS |
$3.73 |
$14,920 |
D/D |
(4,000) |
347,512 |
|
2% |
|
| Gustafson Kurt A |
EVP & Chief Financial Officer |
• – – |
2021-02-22 |
4 |
AS |
$3.73 |
$14,920 |
D/D |
(4,000) |
437,134 |
|
2% |
|
| Turgeon Joseph W. |
CEO & President |
• • – |
2021-02-22 |
4 |
AS |
$3.73 |
$27,975 |
D/D |
(7,500) |
633,362 |
|
2% |
|
| Riga Thomas J |
EVP, COO & CCO |
• – – |
2021-02-22 |
4 |
AS |
$3.73 |
$18,650 |
D/D |
(5,000) |
454,650 |
|
2% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2021-02-19 |
4 |
AS |
$3.64 |
$11,984 |
D/D |
(3,295) |
351,512 |
|
2% |
|
| Gustafson Kurt A |
EVP & Chief Financial Officer |
• – – |
2021-02-19 |
4 |
AS |
$3.64 |
$16,992 |
D/D |
(4,672) |
441,134 |
|
2% |
|
| Turgeon Joseph W. |
CEO & President |
• • – |
2021-02-19 |
4 |
AS |
$3.64 |
$26,394 |
D/D |
(7,257) |
640,862 |
|
2% |
|
658 Records found
|
|
Page 4 of 27 |
|
|
